PRO-based monitoring identified regimen-specific adverse event profiles and persistence of neuropathy, dysgeusia, and nail changes months after breast cancer chemotherapy.
Does PRO-based monitoring capture persistent adverse events after perioperative chemotherapy in breast cancer patients?
Incorporating structured PRO-based questionnaires into follow-up care reveals persistent symptoms beyond chemotherapy completion, which may be crucial for optimizing supportive management.
Absolute Event Rate: 0% vs 0%
PROs are thought to capture persistent symptoms that are often underestimated in conventional clinical practice. In the present breast cancer series, PRO-based monitoring revealed regimen-specific AE profiles and the persistence of neuropathy, dysgeusia, and nail changes beyond chemotherapy. These findings highlight the importance of monitoring not only during chemotherapy, but also in the months after the chemotherapy's completion, when patients continue to suffer from persistent symptoms. Incorporating structured PRO-based questionnaires into follow-up care may be crucial for optimizing supportive management.
FUJII et al. (Wed,) reported a other. PRO-based monitoring identified regimen-specific adverse event profiles and persistence of neuropathy, dysgeusia, and nail changes months after breast cancer chemotherapy.